GlassScriptPhysician profile
Stephen Michael Tait
NPI 1376534164
$3,060.50
in general payments reported to CMS, 2019-2025
28 companies · $961 in 2025
The $961 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $176 · 2021: $375 · 2022: $184 · 2023: $409 · 2024: $635 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $707.60 | 2019-2025 | Unity, Clareon, Hydrus Microstent |
| Regeneron Healthcare Solutions, INC. | $459.43 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $373.98 | 2022-2025 | Syfovre |
| Abbvie INC. | $297.02 | 2022-2025 | Ozurdex, Durysta, Lumigan |
| Allergan, INC. | $159.99 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $135.90 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $86.90 | 2019-2023 | Tecnis Iol |
| Genentech USA, INC. | $82.45 | 2023-2025 | Vabysmo |
| Eyevance Pharmaceuticals LLC | $77.91 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $75.41 | 2024-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| New World Medical,INC. | $68.96 | 2021-2024 | Clearpath, Streamline, Kahook Dual Blade |
| Lensar, INC. | $62.75 | 2025 | Lensar Laser System |
| Kala Pharmaceuticals, INC. | $61.97 | 2021 | |
| Biotissue Holdings INC. | $53.93 | 2024-2025 | |
| Dompe US, INC. | $48.90 | 2024-2025 | Oxervate |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $40.37 | 2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $32.33 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $28.75 | 2024 | Wainua |
| Sun Pharmaceutical Industries INC. | $27.01 | 2021-2024 | |
| Astellas Pharma US INC | $26.98 | 2024 | Izervay |
| Amgen INC. | $23.98 | 2025 | Tepezza |
| Rayner Intraocular Lenses Limited | $23.94 | 2024 | Rayone Spheric, Omidria, Rayone Aspheric |
| Rxsight INC | $23.76 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Sight Sciences, INC. | $18.65 | 2024 | Omni Surgical System |
| Lkc Technologies, INC. | $17.74 | 2025 | |
| Harrow Eye, LLC | $16.31 | 2025 | Iheezo |
| Biogen, INC. | $15.25 | 2024 | Byooviz |
| Beaver-Visitec International, INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Tait listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.